

Vosoritide acetate

Chemical Properties

CAS No. :

Formula: C176H290N56O51S3.C2H4O2

Molecular Weight: 4162.78

Storage: Keep away from moisture Keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.

Biological Description

Description	Vosoritide acetate is a peptide drug designed based on a C-type natriuretic peptide analog. Vosoritide acetate promotes cGMP production by activating the natriuretic peptide receptor-B while antagonizing the inhibitory effects of the FGFR3 signaling pathway on bone growth. Vosoritide acetate is currently used to treat growth disorders such as achondroplasia.
Targets(IC50)	FGFR

Solubility Information

Solubility	H2O: 100 mg/mL (24.02 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.2402 mL	1.2011 mL	2.4022 mL
5 mM	0.048 mL	0.2402 mL	0.4804 mL
10 mM	0.024 mL	0.1201 mL	0.2402 mL
50 mM	0.0048 mL	0.024 mL	0.048 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Duggan S. Vosoritide: First Approval. *Drugs*. 2021 Nov;81(17):2057-2062.

Shuhaibar LC, et al. Phosphatase inhibition by LB-100 enhances BMN-111 stimulation of bone growth. *JCI Insight*. 2021 May 10;6(9):e141426.

Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. *Am J Hum Genet*. 2012 Dec 7;91(6):1108-14.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481